PRZOOM - /newswire/ - Amsterdam, North Holland, Netherlands, 2015/09/10 - Leader Biomedical has approval to start distributing its tissue graft products for orthopaedic and dental applications in Switzerland - LeaderBiomedical.com.

European Medical Contract Manufacturing BV, a Leader Biomedical Group company, has received regulatory approval from Swissmedic to place its range of eTiss® human allografts for dental and orthopaedic applications on the Swiss market.

Using its proprietary eCOO® Technology, Leader Biomedical is able to produce a range of bioresorbable grafts for the Orthopaedic and Dental markets. The eCOO® Technology platform is a milder alternative to cleaning, sterilising, and impregnating human and animal derived bone and tissue using supercritical carbon dioxide (scCO2) instead of harsh chemicals. Grafts processed with eCOO® Technology exhibit certain bio-molecular and mechanical characteristics, such as slower protein degradation, better cell adhesion, superior tensile strength and torque, which make it ideal for indications requiring a graft with weight bearing and tension-sensitive requirements.

The registration was filed at the request of one of its dental customers, a Swiss company active in regenerative care.

About Leader Biomedical

Leader Biomedical (leaderbiomedical.com) seeks to become the leading provider of biomaterials and medical implant solutions. Our mission is to bring next generation technologies, products and healthcare solutions to global markets, with an emphasis on high-growth markets.

Agency / Source: Leader Biomedical

PREMIUM Article / Social Media:

•  Follow Leader Biomedical (@LeaderBiomed) on Twitter
•  Connect Leader Biomedical (Leader Biomedical) via Linkedin

Availability: All Regions (Including Int'l)

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

Distribution / Indexing: [+]